Skip to main content

Table 1 Characteristic of patients newly and chronically treated with MTX

From: Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3adenosine receptor expression

Characteristic RA patients
  Newly MTX treated Chronically MTX treated
Age (years) 48.5 ± 5.89 59.58 ± 2.42
Disease duration (years) 4.37 ± 2.07 6.6 ± 0.97
CRP (mg/l) 10.75 ± 2.01 9.04 ± 1.65
ESR (mm/hour) 31.75 ± 0.63 33.3 ± 4.39
Swollen joint count 13.25 ± 2.56 3.19 ± 0.88
Tender joint count 10.5 ± 2.63 5 ± 0.86
Patient global assessment (VAS)   32.26 ± 4.41
CRP (DAS28-4)   3.23 ± 0.31
ESR (DAS28-4)   4.11 ± 0.3
  1. Values are expressed as mean ± standard error. CRP, C-reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; MTX, methotrexate; RA, rheumatoid arthritis; VAS, visual analogue scale.